4D-150 IVT (3E10 vg/eye) + EYLEA® (aflibercept) Injection 2 mg (0.05mL)
Phase 3Recruiting 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Macular Neovascularization Secondary to Age-Related Macular Degeneration
Conditions
Macular Neovascularization Secondary to Age-Related Macular Degeneration
Trial Timeline
Mar 3, 2025 → Jun 1, 2028
NCT ID
NCT06864988About 4D-150 IVT (3E10 vg/eye) + EYLEA® (aflibercept) Injection 2 mg (0.05mL)
4D-150 IVT (3E10 vg/eye) + EYLEA® (aflibercept) Injection 2 mg (0.05mL) is a phase 3 stage product being developed by 4D Molecular Therapeutics for Macular Neovascularization Secondary to Age-Related Macular Degeneration. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06864988. Target conditions include Macular Neovascularization Secondary to Age-Related Macular Degeneration.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07064759 | Phase 3 | Recruiting |
| NCT06864988 | Phase 3 | Recruiting |
Competing Products
20 competing products in Macular Neovascularization Secondary to Age-Related Macular Degeneration
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| IVT aflibercept + Sham SC + SC CLS-TA | Clearside Biomedical | Phase 2 | 44 |
| CLS-AX + Anti-VEGF | Clearside Biomedical | Phase 1/2 | 33 |
| 4 mg CLS-TA + Sham + IVT aflibercept | Clearside Biomedical | Phase 2 | 44 |
| suprachoroidal CLS-TA + suprachoroidal sham + Lucentis or Avastin | Clearside Biomedical | Phase 3 | 69 |
| CLS-AX + Aflibercept | Clearside Biomedical | Phase 2 | 44 |
| Eylea + ALT-L9 | Alteogen | Phase 1 | 33 |
| KVD001 Injection | KalVista Pharmaceuticals | Phase 2 | 47 |
| KVD001 Injection | KalVista Pharmaceuticals | Phase 1 | 28 |
| FYB203 2 mg (0.05 mL of 40 mg/mL) | Formycon AG | Approved | 77 |
| FYB201 0.5 mg (0.05 mL of 10 mg/mL) | Formycon AG | Approved | 77 |
| UBX1325 injection 50 μL + EYLEA® (aflibercept) Injection 2 mg (0.05mL) | Unity Biotechnology | Phase 2 | 44 |
| UBX1325 | Unity Biotechnology | Phase 2 | 44 |
| Aflibercept + foselutoclax | Unity Biotechnology | Phase 2 | 44 |
| UBX1325 | Unity Biotechnology | Phase 1 | 25 |
| CT-P42 + Eylea | Celltrion | Phase 3 | 77 |
| Faricimab + Aflibercept | Chugai Pharmaceutical | Phase 3 | 77 |
| Faricimab + Aflibercept | Chugai Pharmaceutical | Phase 3 | 77 |
| DS-7080a + Ranibizumab | Daiichi Sankyo | Phase 1 | 33 |
| Fovista® + bevacizumab + ranibizumab + aflibercept | Astellas Pharma | Phase 2 | 52 |
| MA09-hRPE | Astellas Pharma | Pre-clinical | 23 |